title: Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.
abstract: The effect on the IGF system of 60 mg and 600 mg daily of raloxifene administered for 2 weeks prior to surgery was investigated in 37 postmenopausal women with breast cancer. Raloxifene significantly decreased insulin-like growth factor (IGF-I) as compared to placebo (P < 0.05) with no dose-response relationship. No significant change was observed in IGFBP-3, while the IGF-I/IGFBP-3 molar ratio was decreased by treatment, with a statistically significant effect only for the higher dose. Given that high plasma levels of IGF-I have been suggested as a risk factor for breast cancer, these findings provide further support for the potential activity of raloxifene in breast cancer prevention.
authors.affiliation: Division of Chemoprevention, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Torrisi
authors.forename: L
authors.initials: L
authors.lastname: Baglietto
authors.forename: H
authors.initials: H
authors.lastname: Johansson
authors.forename: G
authors.initials: G
authors.lastname: Veronesi
authors.forename: B
authors.initials: B
authors.lastname: Bonanni
authors.forename: A
authors.initials: A
authors.lastname: Guerrieri-Gonzaga
authors.forename: B
authors.initials: B
authors.lastname: Ballardini
authors.forename: A
authors.initials: A
authors.lastname: Decensi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008408:Mastectomy; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood*; D017698:Postmenopause; D011292:Premedication; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D018972:Insulin-Like Growth Factor Binding Protein 3; D009363:Neoplasm Proteins; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D007334:Insulin-Like Growth Factor I